On October 13, 2025, AbbVie Inc. announced two significant developments: the FDA approved an updated indication statement for RINVOQ, expanding its use for adults with moderately to severely active Inflammatory Bowel Disease, and the company will present new data from its antibody-drug conjugate (ADC) platform at the upcoming ESMO 2025 Congress, highlighting advances in targeted therapies for solid tumors[3][4][7]. These major announcements reinforce AbbVie's leadership in immunology and oncology and are likely to support investor sentiment. The last available closing price for ABBV was $230.50 on October 10, 2025, reflecting a slight decline of -0.08% from the previous session, with no explicit price movement attributed to these news events in the provided context.